Wuxi Apptec Co Unsp/Adr (WUXAY) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, everyone. Welcome to the second half earnings call for Wuxi Apptech, the leading CDMO in China. My name is Lawrence Tam, China Healthcare Analyst at Morgan Stanley. First, I want to congratulate management for another strong quarter. This represents two consecutive quarters of beating consensus estimates. The company also reported a substantial rise in backlog, driven by its chemistry and, in particular, its ties business. Investors may have noticed from the company's PPT that Aptek raised its full-year revenue growth guidance by 2 to 3 percentage points to a range of 13 to 17% full-year revenue growth. With that, let me introduce Aptek's management team who will be presenting today. First, we have Mr. Mingzhang Chen, co-CEO, and Mr. Steve Yang, co-CEO, Ms. Florence Shi, CFO, Mr. Howard Wu, General Counsel, Ms. Min Han, the Board Secretary, and Ms. Reija Tang, IR Director. Now, let me turn it over to Reija. Please, Reija. Okay. Thank you, Lawrence. And thank you to all the investors and analysts for joining today's earnings call. We're sharing our 2025 interim results presentation, which you can also find on our website. During today's call, we will make forward-looking statements. Although we believe that our predictions are reasonable, future events are uncertain and our forward-looking statements may turn out to be incorrect. Accordingly, we are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. In addition, to supplement the company's consolidated financial statements presented in accordance with IFRS, We provide adjusted non-FRS financial data. We believe the adjusted financial measures are useful for understanding and assessing our core business performance, and we believe that in...